A Phase I Trial Evaluating the Effects of Plerixafor (AMD3100) and G-CSF in Combination With Azacitidine (Vidaza) for the Treatment of MDS

Trial Profile

A Phase I Trial Evaluating the Effects of Plerixafor (AMD3100) and G-CSF in Combination With Azacitidine (Vidaza) for the Treatment of MDS

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Azacitidine (Primary) ; Filgrastim (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Plerixafor (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 13 Jun 2016 Planned End Date changed from 1 Mar 2014 to 1 Mar 2017.
    • 25 Mar 2013 Planned number of patients changed from 26 to 28 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top